Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note | Alive

Total Raised


Last Raised

$830K | 2 yrs ago

About Comphya

Comphya is a therapy to restore erectile function. Comphya technology consists of implanting a neuro-stimulator in the pelvic cavity, which will selectively activate the nerve to trigger penile erection. The device will provide self-controlled stimulation to the cavernous nerve to restore natural erectile function.

Comphya Headquarters Location

EFPL Innovation Park Bâtiment C

Lausanne, 1015,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Comphya

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Comphya is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,494 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Comphya Patents

Comphya has filed 2 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Penis
  • Phosphodiesterase inhibitors
patents chart

Application Date

Grant Date


Related Topics




Piperazines, Penis, Psychiatric diagnosis, Implants (medicine), Phosphodiesterase inhibitors


Application Date


Grant Date



Related Topics

Piperazines, Penis, Psychiatric diagnosis, Implants (medicine), Phosphodiesterase inhibitors



Latest Comphya News

Cirtec makes Nuvectra neuromed device info available to customers

Feb 2, 2021

February 2, 2021 The Algovita spinal cord stimulation system, which Cirtec Medical bought from Nuvectra in 2020 (Image from Nuvectra) Cirtec Medical is making proprietary information about a neuromodulation device — purchased from bankrupt Nuvectra — available to customers seeking regulatory approval for similar devices. The decision, announced Monday, involved removing the FDA premarket approval for the Nuvectra Algovita spinal cord stimulation system and putting that information into a master file housed at the agency. This allows Cirtec to give its customers access to the Algovita information so they can use it to develop new technologies. For example, if a startup that has a development agreement with Cirtec wants to run a preclinical or clinical trial based on the Algovita technology, that startup can cite the past studies in the master file in its submission for an FDA investigational device exemption application, Cirtec CEO Brian Highley told Medical Design & Outsourcing. Cirtec bought Algovita to add it to its Simplifi neuromodulation R&D platform than to commercialize Algovita directly. As a contract manufacturer, Cirtec is not in a position to do postmarket surveillance, Highley said. It also sells components of the system. “Very basically, we can take the device and sell off-the-shelf components under this master file and get them in the hands of one of our customers quickly,” Highley said. “It’s also customizable, so if you need a smaller device or different configurations, we can easily modify the system for them.” Cirtec has several customers interested in the technology, which they can obtain from the FDA with Cirtec’s permission. Plano, Texas-based Nuvectra filed for Chapter 11 bankruptcy protection in November 2019 and Cirtec bought the Algovita intellectual property and certain assets from Nuvectra in May 2020. Cirtec was not among Nuvectra’s creditors, Highley noted. Two contract manufacturers with unsecured claims were Minnetronix Medical  and  Greatbatch Medical , now a part of  Integer Holdings  (NYSE: ITGR ). Minnetronix was owed nearly $2.8 million, and Greatbatch’s unsecured claim was nearly $2.2 million. Nuvectra began as the QiG Group, a part of Greatbatch Medical before its spinout was approved in February 2016 . But its Algovita device was up against stiff competition in the SCS space, which is dominated by much larger companies — Abbott, Boston Scientific, Medtronic and Nevro. “There’s a lot of innovation going on in neuromodulation, but in order for a startup or somebody in academia to get something to market quickly, they’d have to go to Medtronic, Boston or Abbott,” Highley said. “These guys don’t like to deal with some of the small startups. We were looking for a way of supporting the neuromodulation community and providing an option to get a product in a customer’s hand quickly.” Cirtec’s PMA-to-master-file conversion, which it undertook on the FDA’s advice, is not common, but contract manufacturers have done it before, according to longtime medtech consultant Mark Bonifacio. “That’s a great strategy for the CM, and you’ve really got what you wanted if they get the 510(k) approval or the PMA,” Bonifacio said in an interview with MDO. “It’s not uber-common but it’s definitely not weird or it’s not out of the jurisdiction of the FDA to say this. … I think it’s a good suggestion for Brian and the folks at Cirtec to go down that route.” Cirtec’s move has also drawn praise from others. “Translating neuromodulation research concepts in academia just became much easier,” said University of Minnesota Medical School professor Greg Molnar in a news release . “Having access to Cirtec’s Simplifi clinical neurostimulation system and master file can be leveraged to support physician-sponsored IDE studies that would otherwise not be possible.” “Leveraging Cirtec’s Simplifi neuromodulation platform has enabled Comphya to significantly reduce our cost and time to market by leveraging the existing validation reports and other objective evidence rather than creating our own,” added Cirtec customer Rodrigo Fraga, CEO of Comphya . Tell Us What You Think!

Comphya Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Comphya Rank

  • When was Comphya founded?

    Comphya was founded in 2017.

  • Where is Comphya's headquarters?

    Comphya's headquarters is located at EFPL Innovation Park Bâtiment C, Lausanne.

  • What is Comphya's latest funding round?

    Comphya's latest funding round is Convertible Note.

  • How much did Comphya raise?

    Comphya raised a total of $4.39M.

  • Who are the investors of Comphya?

    Investors of Comphya include Foundation for Technological Innovation, IMD Startup Competition, investiere, Zurcher Kantonalbank and Tech Tour.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.